Pancragen

What is Pancragen?

Pancragen is a synthetic tetrapeptide bioregulator (Lys-Glu-Asp-Trp) developed by Professor Vladimir Khavinson at the St. Petersburg Institute of Bioregulation and Gerontology. It is specifically designed to normalize pancreatic function at the cellular level, targeting both the exocrine and endocrine functions of the pancreas. As a bioregulator peptide, it works through epigenetic mechanisms to restore healthy gene expression patterns in pancreatic tissue.

Mechanism of Action

Pancragen interacts with DNA sequences in pancreatic cells, including beta cells of the islets of Langerhans, to modulate gene expression related to insulin production, glucose metabolism, and cellular repair. The peptide helps restore optimal pancreatic function by influencing transcription factors involved in beta cell maintenance and regeneration. It may also support the exocrine pancreas by normalizing digestive enzyme production.

Potential Benefits

• Blood sugar regulation — May support healthy insulin production and glucose metabolism
• Pancreatic cell support — Promotes beta cell health and function
• Metabolic health — Supports overall metabolic homeostasis through improved pancreatic function
• Digestive support — May normalize exocrine pancreatic function and enzyme production
• Anti-aging — Helps counteract age-related decline in pancreatic function

Research Overview

Pancragen has been studied primarily in Russian bioregulation research. Animal studies have demonstrated its ability to improve glucose tolerance and normalize insulin levels in models of metabolic dysfunction. Clinical observations suggest improvements in blood sugar control and pancreatic enzyme levels in patients receiving Pancragen as part of bioregulatory protocols. The peptide has shown a favorable safety profile in published studies.

Administration

Pancragen is reconstituted with 3ml of bacteriostatic water. Using an insulin syringe marked 1-100 units, draw 10 units for a daily dose. One 20mg vial provides 30 days of dosing. Protocol: 3 months on, 9 months off. Administered subcutaneously.